Search

Your search keyword '"Abbey, Selim"' showing total 13 results
Start Over Author "Abbey, Selim"
13 results on '"Abbey, Selim"'

2. The cardiac blood transcriptome predicts de novo onset of atrial fibrillation in heart failure

Author

Lamirault, Guillaume, Fellah-Hebia, Imen, Chevalier, Catherine, Guisle, Isabelle, Guyomarc'h, Béatrice, Solnon, Aude, Gourraud, Jean-Baptiste, Desprets, Laurent, Abbey, Selim, Leclercq, Christophe, Bru, Paul, Milhem, Antoine, Billon, Olivier, Anselme, Frederic, Savouré, Arnaud, Trochu, Jean-Noël, Houlgatte, Rémi, Lande, Gilles, and Steenman, Marja

Published
2024
Full Text
View/download PDF

4. Recurrences of Atrial Fibrillation Despite Durable Pulmonary Vein Isolation: The PARTY-PVI Study

Author

Benali, Karim, Barré, Valentin, Hermida, Alexis, Galand, Vincent, Milhem, Antoine, Philibert, Séverine, Boveda, Serge, Bars, Clément, Anselme, Frédéric, Maille, Baptiste, André, Clémentine, Behaghel, Albin, Moubarak, Ghassan, Clémenty, Nicolas, Da Costa, Antoine, Arnaud, Marine, Venier, Sandrine, Sebag, Frédéric, Jésel-Morel, Laurence, Sagnard, Audrey, Champ-Rigot, Laure, Dang, Duc, Guy-Moyat, Benoit, Abbey, Selim, Garcia, Rodrigue, Césari, Olivier, Badenco, Nicolas, Lepillier, Antoine, Ninni, Sandro, Boulé, Stéphane, Maury, Philippe, Algalarrondo, Vincent, Bakouboula, Babé, Mansourati, Jacques, Lesaffre, François, Lagrange, Philippe, Bouzeman, Abdeslam, Muresan, Lucian, Bacquelin, Raoul, Bortone, Agustin, Bun, Sok-Sithikun, Pavin, Dominique, Macle, Laurent, and Martins, Raphaël P.

Published
2023
Full Text
View/download PDF

5. Exclusion of Intra-Atrial Thrombus Diagnosis Using D-Dimer Assay Before Catheter Ablation of Atrial Fibrillation

Author

Al Arnaout, Alain, Amara, Walid, Amelot, Mathieu, Bars, Clément, Becoulet, Lucile, Bru, Paul, Chevalier, Philippe, Darmon, Jean-Philippe, Deharo, Jean-Claude, Dompnier, Antoine, Duplantier-Duchene, Cécile, Extramiana, Fabrice, Faugier, Jean-Paul, Guenancia, Charles, Horvilleur, Jérôme, Jourda, François, Laurent, Gabriel, Lellouche, Nicolas, Magnin Poull, Isabelle, Piot, Olivier, Roux, Antoine, Saludas, Yannick, Seitz, Julien, Taieb, Jérôme, Milhem, Antoine, Ingrand, Pierre, Tréguer, Frédéric, Cesari, Olivier, Da Costa, Antoine, Pavin, Dominique, Rivat, Philippe, Badenco, Nicolas, Abbey, Sélim, Zannad, Noura, Winum, Pierre François, Mansourati, Jacques, Maury, Philippe, Bader, Hugues, Savouré, Arnaud, Sacher, Frédéric, Andronache, Marius, Allix-Béguec, Caroline, De Chillou, Christian, and Anselme, Frédéric

Published
2019
Full Text
View/download PDF

6. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study

Author

Ekanem, Emmanuel, Neuzil, Petr, Reichlin, Tobias, Kautzner, Joseph, van der Voort, Pepijn, Jais, Pierre, Chierchia, Gian-Battista, Bulava, Alan, Blaauw, Yuri, Skala, Tomas, Fiala, Martin, Duytschaever, Mattias, Szeplaki, Gabor, Schmidt, Boris, Massoullie, Grégoire, Neven, Kars, Thomas, Olivier, Vijgen, Johan, Gandjbakhch, Estelle, Scherr, Daniel, Johannessen, Arne, Keane, David, Boveda, Serge, Maury, Philippe, García-Bolao, Ignacio, Anic, Ante, Hansen, Peter Steen, Raczka, Franck, Lepillier, Antoine, Guyomar, Yves, Gupta, Dhiraj, Van Opstal, Jurren, Defaye, Pascal, Sticherling, Christian, Sommer, Philipp, Kucera, Pavel, Osca, Joaquin, Tabrizi, Fariborz, Roux, Antoine, Gramlich, Michael, Bianchi, Stefano, Adragão, Pedro, Solimene, Francesco, Tondo, Claudio, Russo, Antonio Dello, Schreieck, Jürgen, Luik, Armin, Rana, Obaida, Frommeyer, Gerrit, Anselme, Frédéric, Kreis, Ingo, Rosso, Raphael, Metzner, Andreas, Geller, Laszlo, Baldinger, Samuel H., Ferrero, Angel, Willems, Stephan, Goette, Andreas, Mellor, Greg, Mathew, Shibu, Szumowski, Lukasz, Tilz, Roland, Iacopino, Saverio, Jacobsen, Peter Karl, George, Andrikopoulos, Osmancik, Pavel, Spitzer, Stefan, Balasubramaniam, Richard, Parwani, Abdul Shokor, Deneke, Thomas, Glowniak, Andrzej, Rossillo, Antonio, Pürerfellner, Helmut, Duncker, David, Reil, Peter, Arentz, Thomas, Steven, Daniel, Olalla, Juan José, de Jong, Jonas S. S. G., Wakili, Reza, Abbey, Selim, Timo, Gottschling, Asso, Antonio, Wong, Tom, Pierre, Bertrand, Ewertsen, Niels Christian, Bergau, Leonard, Lozano-Granero, Cristina, Rivero, Maximo, Breitenstein, Alexander, Inkovaara, Jaakko, Fareh, Samir, Latcu, Decebal Gabriel, Linz, Dominik, Müller, Patrick, Ramos-Maqueda, Javier, Beiert, Thomas, Themistoclakis, Sakis, Meininghaus, Dirk Grosse, Stix, Günter, Tzeis, Stylianos, Baran, Jakub, Almroth, Henrik, Munoz, Daniel Rodriguez, de Sousa, João, Efremidis, Michalis, Balsam, Pawel, Petru, Jan, Küffer, Thomas, Peichl, Petr, Dekker, Lukas, Della Rocca, Domenico G., Moravec, Ondrej, Funasako, Moritoshi, Knecht, Sebastien, Jauvert, Gael, Chun, Julian, Eschalier, Romain, Füting, Anna, Zhao, Alexandre, Koopman, Pieter, Laredo, Mikael, Manninger, Martin, Hansen, Jim, O’Hare, Daniel, Rollin, Anne, Jurisic, Zrinka, Fink, Thomas, Chaumont, Corentin, Rillig, Andreas, Gunawerdene, Melanie, Martin, Claire, Kirstein, Bettina, Nentwich, Karin, Lehrmann, Heiko, Sultan, Arian, Bohnen, Jan, Turagam, Mohit K., and Reddy, Vivek Y.

Abstract

Pulsed field ablation (PFA) is an emerging technology for the treatment of atrial fibrillation (AF), for which pre-clinical and early-stage clinical data are suggestive of some degree of preferentiality to myocardial tissue ablation without damage to adjacent structures. Here in the MANIFEST-17K study we assessed the safety of PFA by studying the post-approval use of this treatment modality. Of the 116 centers performing post-approval PFA with a pentaspline catheter, data were received from 106 centers (91.4% participation) regarding 17,642 patients undergoing PFA (mean age 64, 34.7% female, 57.8% paroxysmal AF and 35.2% persistent AF). No esophageal complications, pulmonary vein stenosis or persistent phrenic palsy was reported (transient palsy was reported in 0.06% of patients; 11 of 17,642). Major complications, reported for ~1% of patients (173 of 17,642), were pericardial tamponade (0.36%; 63 of 17,642) and vascular events (0.30%; 53 of 17,642). Stroke was rare (0.12%; 22 of 17,642) and death was even rarer (0.03%; 5 of 17,642). Unexpected complications of PFA were coronary arterial spasm in 0.14% of patients (25 of 17,642) and hemolysis-related acute renal failure necessitating hemodialysis in 0.03% of patients (5 of 17,642). Taken together, these data indicate that PFA demonstrates a favorable safety profile by avoiding much of the collateral damage seen with conventional thermal ablation. PFA has the potential to be transformative for the management of patients with AF.

Published
2024
Full Text
View/download PDF

7. Remote monitoring for cardiac implantable electronic devices: A practical guide

Author

Klein, Cédric, primary, Finat, Loic, additional, Abbey, Selim, additional, Eschalier, Romain, additional, Fossati, Frederic, additional, Lazarus, Arnaud, additional, Marijon, Eloi, additional, Pasquié, Jean-Luc, additional, Ploux, Sylvain, additional, Salerno, Fiorella, additional, Williatte, Lina, additional, Gras, Daniel, additional, Sacher, Frédéric, additional, Taieb, Jérôme, additional, Boveda, Serge, additional, and Guédon-Moreau, Laurence, additional

Published
2022
Full Text
View/download PDF

8. LB-469805-01 TAILORED CARDIAC ABLATION PROCEDURE FOR PERSISTENT ATRIAL FIBRILLATION GUIDED BY ARTIFICIAL INTELLIGENCE: THE TAILORED-AF RANDOMIZED CLINICAL TRIAL

Author

Deisenhofer, Isabel, Albenque, Jean-Paul, Busch, Sonia, Gitenay, Edouard, Mountantonakis, Stavros, Roux, Antoine, Horvilleur, Jerome, Bakouboula, Babé, Oza, Saumil R., Abbey, Selim, Théodore, Guillaume, Lepillier, Antoine, Guyomar, Yves, Bessiere, Francis, Milpied, Paola, Appetiti, Anthony, Guerrero, Daniel, De Potter, Tom, de Chillou, Christian, Goldbarg, Seth H., Verma, Atul, and Hummel, John D.

Published
2024
Full Text
View/download PDF

9. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions:a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)

Author

Fauchier, Laurent, Cinaud, Alexandre, Brigadeau, François, Lepillier, Antoine, Pierre, Bertrand, Abbey, Selim, Fatemi, Marjaneh, Franceschi, Frederic, Guedeney, Paul, Jacon, Peggy, Paziaud, Olivier, Venier, Sandrine, Deharo, Jean Claude, Gras, Daniel, Klug, Didier, Mansourati, Jacques, Montalescot, Gilles, Piot, Olivier, Defaye, Pascal, Lip, Gregory, Collet, Jean-Phillippe, Haude, Michael, Byrne, Robert, Chung, Eugene, Halvorsen, Sigrun, Lau, Dennis, Lopez-Cabanillas, Nestor, Lettino, Maddalena, Marin, Francisco, Obel, Israel, Rubboli, Andrea, Storey, Robert, Valgimigli, Marco, Huber, Kurt, Potpara, Tatjana, Blomström Lundqvist, Carina, Crijns, Harry, Steffel, Jan, Heidbüchel, Hein, Stankovic, Goran, Airaksinen, Juhani, ten Berg, Jurrien, Capodanno, Davide, James, Stefan, Bueno, Hector, Morais, Joao, Sibbing, Dirk, Rocca, Bianca, Hsieh, Ming-Hsiung, Akoum, Nazem, Lockwood, Deborah, Gomez Flores, Jorge Rafael, Jardine, Ronald, Fysiologie, MUMC+: MA Cardiologie (9), Cardiologie, RS: CARIM - R2.01 - Clinical atrial fibrillation, RS: Carim - H01 Clinical atrial fibrillation, Éducation Éthique Santé EA 7505 (EES), Université de Tours (UT), Université Paris Descartes - Paris 5 (UPD5), Hôtel-Dieu, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre cardiologique du Nord (CCN), Griset SA, Diehl - Griset, Nouvelles Cliniques Nantaises, Service de Cardiologie (BREST - Cardio), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de cardiologie, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CHU Grenoble, Service de cardiologie [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Dysoxie, suractivité : aspects cellulaires et intégratifs thérapeutiques (DS-ACI / UMR MD2), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de Cardiologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital cardiologique, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Optimisation des régulations physiologiques (ORPHY (EA 4324)), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), IHU-LIRYC, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux], Cardiac Stimulation and Rhythmology, University of Liverpool, Aalborg University [Denmark] (AAU), Lukaskrankenhaus, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Universidad Nacional de Córdoba [Argentina], San Gerardo Hospital of Monza, Universidad de Murcia, S. Maria delle Croci Hospital, University of Sheffield [Sheffield], University of Bern, Sigmund Freud University (SFU), University of Belgrade [Belgrade], Department of Physiology, Maastricht University, Department of Physiology, Maastricht University [Maastricht]-Maastricht University [Maastricht], University hospital of Zurich [Zurich], and ESC Sci Document Grp

Subjects
Cardiac Catheterization, medicine.medical_treatment, Heart Valve Diseases, ELUTING STENT IMPLANTATION, 030204 cardiovascular system & hematology, VITAMIN-K ANTAGONIST, Left atrial appendage occlusion, Coronary artery disease, [SHS]Humanities and Social Sciences, Percutaneous coronary intervention, 0302 clinical medicine, HAS-BLED SCORES, Risk Factors, Stent, ST-SEGMENT ELEVATION, Position paper, 030212 general & internal medicine, Myocardial infarction, Consensus document, 610 Medicine & health, Stroke, ComputingMilieux_MISCELLANEOUS, BARE-METAL STENTS, European Heart Rhythm Association, AORTIC-VALVE IMPLANTATION, Low molecular weight heparin, Antiplatelet agents, DUAL ANTIPLATELET THERAPY, Atrial fibrillation, Acute coronary syndrome, Anticoagulation, Antithrombotic therapy, Bleeding, Non-Vitamin K antagonist oral anticoagulants, Parenteral anticoagulants, Thromboembolism, Thrombosis, Vitamin K antagonists, Cardiology and Cardiovascular Medicine, Physiology (medical), BLEEDING RISK SCORES, Treatment Outcome, UNINTERRUPTED ORAL ANTICOAGULATION, ACUTE MYOCARDIAL-INFARCTION, medicine.medical_specialty, Consensus, Settore BIO/14 - FARMACOLOGIA, medicine.drug_class, Hemorrhage, Risk Assessment, 03 medical and health sciences, Fibrinolytic Agents, medicine, Humans, Intensive care medicine, business.industry, Anticoagulants, ta3121, medicine.disease, Non-vitamin K antagonist oral anticoagulants, Human medicine, business, Platelet Aggregation Inhibitors
Abstract

In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.

Published
2019
Full Text
View/download PDF

10. Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation

Author

Fauchier, Laurent, primary, Cinaud, Alexandre, additional, Brigadeau, François, additional, Lepillier, Antoine, additional, Pierre, Bertrand, additional, Abbey, Selim, additional, Fatemi, Marjaneh, additional, Franceschi, Frederic, additional, Guedeney, Paul, additional, Jacon, Peggy, additional, Paziaud, Olivier, additional, Venier, Sandrine, additional, Deharo, Jean Claude, additional, Gras, Daniel, additional, Klug, Didier, additional, Mansourati, Jacques, additional, Montalescot, Gilles, additional, Piot, Olivier, additional, and Defaye, Pascal, additional

Published
2018
Full Text
View/download PDF

13. Abstract 14257: De Novo Onset of Atrial Fibrillation in Heart Failure Patients is Predicted by the Blood Transcriptome

Author

Steenman, Marja, Lamirault, Guillaume, Chevalier, Catherine, Guisle, Isabelle, Guyomarch, Beatrice, Fellah-Hebia, Imen, Solnon, Aude, Gourraud, Jean Baptiste, Desprets, Laurent, Abbey, Selim, Leclercq, Christophe, Bru, Paul, Milhem, Antoine, Billon, Olivier, Anselme, Fr?deric, Savour?, Arnaud, Trochu, Jean Noel, Houlgatte, R?mi, and Lande, Gilles

Abstract

Introduction:Heart failure increases the risk of developing atrial fibrillation. Better prediction of this risk may improve treatment strategies. Thus far no transcriptome-based predictor of atrial fibrillation incidence in heart failure has been identified.Hypothesis:We hypothesized that the blood transcriptome profile of heart failure patients is associated with atrial fibrillation incidence.Methods:We enrolled 139 heart failure patients without a history of atrial fibrillation. Coronary sinus blood samples were obtained during biventricular cardioverter defibrillator implantation and were used for whole genome expression profiling using microarrays. Patients were followed up during one year and paroxysmal or persistent atrial fibrillation occurrence was based on interrogation of the defibrillator. Two-class statistical analysis was used to identify genes differentially expressed in patients developing atrial fibrillation during follow-up vs. patients remaining in sinus rhythm. The predictive value of the expression profile was determined using a Mann-Whitney Test.Results:Both clinical and gene expression data could be analyzed for 115 patients: 102 patients stayed in sinus rhythm throughout follow-up while 13 patients developed atrial fibrillation at 1 year follow-up (paroxysmal n=10, persistent n=3). A total of 155 genes was down-regulated in patients developing atrial fibrillation at 1 year follow-up (FDR=0%). The expression levels of these 155 genes were combined to obtain a molecular atrial fibrillation prediction score for each patient. This prediction score distinguished patients that would develop atrial fibrillation within 1 year from patients staying in sinus rhythm (p<0.0001).Conclusions:The blood transcriptome of heart failure patients is a promising tool for the prediction of de novo onset of atrial fibrillation. In line with precision medicine development, the hereby identified high risk patients may benefit from more aggressive clinical management.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results